Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Buprenorphine + Naloxone
Buprenorphine + naloxone
Routinely available
SMC (355/07)
24/06/2026
Indication
For restricted use within NHS Scotland for substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Buprenorphine/naloxone is restricted to those patients in whom methadone is not suitable and for whom the use of buprenorphine is considere...
Therapeutic Area
Central nervous system
Status Description
Routinely available in line with national guidance
Formulation
2mg/0.5mg, 8mg/2mg sublingual tablet
Comments
Refer to pathway or local board guidelines for preferred formulation